Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oral Gram-negative anaerobic bacteria and mixed oral biofilm communities are complex polymicrobial assemblies that colonize the oral cavity, particularly the subgingival environment. These communities are the primary etiological agents of periodontal diseases, including gingivitis and periodontitis, where a shift from aerobic to anaerobic species leads to chronic inflammation and tissue destruction [PMID: 15355360]. Key pathogens within these biofilms, such as Porphyromonas gingivalis and Treponema denticola, employ sophisticated mechanisms like quorum sensing and metabolic cross-feeding to survive and evade the host immune system [PMID: 15125628]. Therapeutic intervention focuses on the mechanical disruption of the biofilm and the use of antimicrobial agents to reduce the load of pathogenic species. However, the protective nature of the biofilm matrix makes these communities significantly more resistant to antibiotics compared to planktonic cells, posing a major challenge in clinical management [PMID: 21762155]. Effective treatment often requires a combination of physical debridement and targeted chemotherapy to restore a healthy microbial balance.
Antimicrobials targeting these communities typically act by inhibiting bacterial cell wall synthesis (e.g., beta-lactams), disrupting protein synthesis (e.g., tetracyclines), or interfering with DNA replication (e.g., metronidazole) [PMID: 15355360]. Additionally, antiseptic agents like chlorhexidine disrupt the bacterial cell membrane and prevent biofilm attachment [PMID: 28203155].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oral Gram-negative anaerobic bacteria and mixed oral biofilm communities.